ORR Achieves 62.5%
Cases of Complete Remission Observed After Low-Dose Administration

GcCell's CD5-targeted CAR-NK cell therapy candidate, "GCC2005," achieved an objective response rate (ORR) of 62.5% in an early-stage clinical trial for patients with relapsed or refractory NK/T-cell lymphoma. There were also cases where patients reached complete remission after receiving a low dose and maintained their response for 18 months.

Professor Deokhyun Yoon of the Department of Oncology at Asan Medical Center Seoul is presenting on the topic of 'Overcoming Resistance in T-cell Malignancies: From Phase 1 Study of CD5-targeted Allogeneic CAR-NK Cells' at ICBMT 2026. GC Cell

Professor Deokhyun Yoon of the Department of Oncology at Asan Medical Center Seoul is presenting on the topic of 'Overcoming Resistance in T-cell Malignancies: From Phase 1 Study of CD5-targeted Allogeneic CAR-NK Cells' at ICBMT 2026. GC Cell

View original image

On September 21, GcCell announced that it had presented the interim results from its Phase 1a clinical trial of GCC2005 in an oral presentation at the International Congress of Blood and Marrow Transplantation (ICBMT 2026), held at BEXCO in Busan on September 17.


As of the data cutoff on October 31, 2025, a total of nine patients had been enrolled in the clinical trial. Out of eight patients who were evaluable for tumor response, five showed a treatment response, resulting in an ORR of 62.5%. Among them, three patients achieved complete remission (CR), and two showed partial remission (PR).


In particular, one patient with angioimmunoblastic T-cell lymphoma (AITL) who had relapsed after three previous treatments reached complete remission following low-dose administration and has maintained this response for 18 months. Another patient, who had a large tumor burden before treatment, also achieved complete remission within a short period after administration, with the tumor disappearing rapidly.


In the initial safety assessment, no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GvHD) were reported.


This presentation also disclosed the rationale for selecting CD5 as a target, the CAR construct development process, and the results of in vitro and in vivo analyses of GCC2005, sharing early-stage research and development achievements.


GCC2005 is a CD5-targeted, allogeneic CAR-NK cell therapy candidate that GcCell is developing as a first-in-class global innovative drug. The company has completed dosing for all participants in the Phase 1a clinical trial in Korea and is preparing to initiate Phase 1b.


Deokhyun Yoon, Professor of Oncology at Asan Medical Center in Seoul, stated, "Relapsed or refractory T-cell lymphoma is a difficult-to-treat disease with limited therapeutic options after multiple rounds of treatment. Since GCC2005 has shown treatment response and cases of long-term complete remission in early clinical trials, it is necessary to further verify these possibilities in subsequent clinical studies."



Sungyong Won, CEO of GcCell, commented, "We continue to share the clinical achievements of GCC2005 at major international conferences and discuss their clinical significance with experts. We will push forward with the Phase 1b study as planned, continuing development toward a global registration trial."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing